Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

House Investigation Of COX-2 Promotional Practices Turns Attention To Pfizer

This article was originally published in The Pink Sheet Daily

Executive Summary

Government Reform Committee members discuss extending their investigation on Vioxx promotional practices to other COX-2 drugs. FDA Office of New Drugs' Jenkins rebukes Merck for avoiding discussion of certain cardiovascular risk data during physician detailing visits before a 2002 Vioxx labeling change.

You may also be interested in...



Vioxx Detailing Practices Questioned In Independent Review

Report contracted by Merck finds company’s senior management acted with integrity relating to development, testing and marketing of the COX-2 inhibitor, however.

Vioxx Detailing Practices Questioned In Independent Review

Report contracted by Merck finds company’s senior management acted with integrity relating to development, testing and marketing of the COX-2 inhibitor, however.

Merck CEO Clark Brings Managed Care Expertise To Post; Gilmartin Retires

Richard Clark's appointment signals the importance Merck is placing on managed care ahead of the January 2006 start of the Medicare drug benefit. Merck also is highlighting Clark's manufacturing expertise, but acknowledges he will rely on Merck Research Labs President Peter Kim for advice on R&D strategy.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel